【券商聚焦】华源证券维持巨子生物“买入”评级指公司医美管线持续丰富

金吾财讯01-22

（原标题：【券商聚焦】华源证券维持巨子生物(02367.HK)“买入”评级指公司医美管线持续丰富）金吾财讯|华源证券发布研报指，巨子生物(02367.HK)全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品获批，为公司第二张医美三类医疗器械证。该产品适用于真皮层注射以改善面颊部平滑度，由重组I型α1亚型胶原蛋白及透明质酸钠复合溶液组成，规格为1.5mL/支至3.0mL/支。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605117704?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-22 11:44","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2605117704","market":"hk","top_or_hot":-1,"title":"【券商聚焦】华源证券维持巨子生物“买入”评级 指公司医美管线持续丰富","media":"金吾财讯","content":"<div>\n<p>（原标题：【券商聚焦】华源证券维持巨子生物(02367.HK)“买入”评级 指公司医美管线持续丰富）金吾财讯|华源证券发布研报指，巨子生物(02367.HK)全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品获批，为公司第二张医美三类医疗器械证。该产品适用于真皮层注射以改善面颊部平滑度，由重组I型α1亚型胶原蛋白及透明质酸钠复合溶液组成，规格为1.5mL/支至3.0mL/支。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122121142a4482f8f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】华源证券维持巨子生物“买入”评级 指公司医美管线持续丰富</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】华源证券维持巨子生物“买入”评级 指公司医美管线持续丰富\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-22 11:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122121142a4482f8f&s=b><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（原标题：【券商聚焦】华源证券维持巨子生物(02367.HK)“买入”评级 指公司医美管线持续丰富）金吾财讯|华源证券发布研报指，巨子生物(02367.HK)全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品获批，为公司第二张医美三类医疗器械证。该产品适用于真皮层注射以改善面颊部平滑度，由重组I型α1亚型胶原蛋白及透明质酸钠复合溶液组成，规格为1.5mL/支至3.0mL/支。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122121142a4482f8f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122121142a4482f8f&s=b","article_id":"2605117704","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122121142a4482f8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605117704","pubTimestamp":1769053454,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"当前公司已积累2个重组胶原医美三械产品，医美管线持续丰富，医美板块Ⅲ类械重组胶原蛋白产品获批后或带来较大边际催化弹性。维持“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02367":"巨子生物"},"translate_title":"[Brokerage Focus] Huayuan Securities maintains Juzi Biotech's \"buy\" rating, indicating that the company's medical beauty pipeline continues to enrich","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1.5},"content_text":"（原标题：【券商聚焦】华源证券维持巨子生物(02367.HK)“买入”评级 指公司医美管线持续丰富）金吾财讯|华源证券发布研报指，巨子生物(02367.HK)全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品获批，为公司第二张医美三类医疗器械证。该产品适用于真皮层注射以改善面颊部平滑度，由重组I型α1亚型胶原蛋白及透明质酸钠复合溶液组成，规格为1.5mL/支至3.0mL/支。 公司所处重组胶原蛋白赛道具备高景气度，首个三械医美产品重组I型α1亚型胶原蛋白冻干纤维已于2025年10月获批，用于面部真皮组织填充以纠正额部动力性皱纹。当前公司已积累2个重组胶原医美三械产品，医美管线持续丰富，医美板块Ⅲ类械重组胶原蛋白产品获批后或带来较大边际催化弹性。 华源证券预计公司2025-2027年归母净利润分别为19.3/22.6/25.4亿元，同比变动-6.3%/+17.0%/+12.3%。2026年1月20日收盘价为35.40港元，一年内最高/最低价分别为87.10/32.88港元，总市值为37,910.00百万港元，资产负债率为18.58%。维持“买入”评级。 风险提示包括化妆品行业竞争加剧风险、渠道竞争加剧风险及新品孵化风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605117704","isCrawlerRequest":true}

【券商聚焦】华源证券维持巨子生物“买入”评级 指公司医美管线持续丰富

精彩评论

【券商聚焦】华源证券维持巨子生物“买入”评级指公司医美管线持续丰富